Hyperthermia during isoflurane anaesthesia in a horse with suspected hyperkalaemic periodic paralysis

Cornick, J L; Seahorn, Thomas L.; Hartsfield, Sandee M.

doi:10.1111/j.2042-3306.1994.tb04061.x

Cited by 24 publications

(33 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The disease has been induced by halothane alone or in combination with succinylcholine or painful stimuli 8,10,15,16 . An additional case, a 12‐day‐old Quarter Horse filly with suspected HYPP developed mild hypercapnia, hyperthermia, and increased muscle enzyme activity while under isoflurane anesthesia 18 . In our study, 5 horses with confirmed MHS developed clinical and laboratory abnormalities consistent with MH that resulted in death while under halothane or isoflurane anesthesia.…”

Section: Discussionmentioning

confidence: 55%

See 1 more Smart Citation

Malignant Hyperthermia Associated with Ryanodine Receptor 1 (C7360G) Mutation in Quarter Horses

Aleman¹,

Nieto²,

Magdesian³

2009

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Anesthetic-induced malignant hyperthermia (MH) has been documented in Quarter Horses with a single point mutation in the ryanodine receptor 1 gene (RyR1) at nucleotide C7360G, generating a R2454G amino acid substitution. However, there have been no reports of nonanesthetic manifestations of MH in horses with the C7360G mutation.Objective: To describe clinical manifestations of Quarter Horses with the C7360G mutation. Animals: Eleven Quarter Horses with the RyR1 C7360G mutation.Methods: This prospective study included horses with suspected MH, undetermined etiology of sudden death, death within hours of onset of rhabdomyolysis, muscle rigidity, stiffness, intermittent sweating, and persistent increases in serum muscle enzyme activities. Whole blood in EDTA and skeletal muscle were processed for genetic and histochemical analysis. Medical records and pedigrees were collected when available.Results: Both anesthetic-and non-anesthetic-associated myopathic manifestations of MH occurred in halter Quarter Horses with mutation of RyR1. The disease is inherited as an autosomal dominant trait. Clinical and laboratory abnormalities were similar in both forms. Rhabdomyolysis was a common finding in both groups of horses. Skeletal muscle histochemical findings were nonspecific and compatible with a noninflammatory myopathic process.Conclusions and Clinical Importance: MH is a potentially fatal disease of Quarter Horses that could be triggered by halogenated anesthetics and other nonanesthetic factors that may include exercise, stress, breeding, illnesses, and concurrent myopathies.

show abstract

Section: Discussionmentioning

confidence: 55%

“…The 1st report of the disease in horses occurred in 1975, 8 and since then other cases have been documented 9–19 . Reported breeds include Quarter Horse, Thoroughbred, Appaloosa, Arabian, and ponies.…”

mentioning

confidence: 99%

Malignant Hyperthermia Associated with Ryanodine Receptor 1 (C7360G) Mutation in Quarter Horses

Aleman¹,

Nieto²,

Magdesian³

2009

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…26 Since the onset of use of inhalation anesthesia in horses, cases of MH 16 have been suspected but seldom reported. The reported breeds are Quarter Horse, 5,21,32 Thoroughbred,17,21,43 Appaloosa, 21 Arab, 15 and ponies. 13,14 To date, the diagnosis of MH in horses is based on characteristic clinical manifestations triggered by halothane, 16,21,37,43 or abnormalities in the in vitro contracture test using halothane, succinylcholine, and caffeine.…”

mentioning

confidence: 96%

Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia

et al. 2004

View full text Add to dashboard Cite

Equine malignant hyperthermia MH has been suspected but never genetically confirmed. In this study, we investigated whether mutations in a candidate gene, RyR1, were associated with MH in two clinically affected horses. RyR1 gene sequences revealed polymorphisms in exons 15, 17, and 46 in WTRyR1 and MHRyR1 horses with one derived amino acid change in MHRyR1 exon 46, R2454G. The MHRyR1 horses were genetically heterozygous for this mutation, but presented an MH phenotype with halothane challenge. Skeletal sarcoplasmic reticulum from a R2454G heterozygote collected during a fulminant MH episode showed significantly higher affinity and density of [3H]ryanodine-binding sites compared to WTRyR1, but no differences in Ca2+, Mg2+, and caffeine modulation. In conclusion, an autosomal missense mutation in RyR1 is associated with MH in the horse, providing a screening test for susceptible individuals. [3H]ryanodine-binding analysis suggests that long-lasting changes in RyR1 conformation persists in vitro after the triggering event.

show abstract

“…1995). Cornick et al. (1994) documented an episode of suspected HYPP during general anaesthesia, following a previous uneventful anaesthetic, though the diagnosis of HYPP was not confirmed.…”

Section: Introductionmentioning

confidence: 99%

“…1995; Bailey et al. 1996; Baetge 2007), of these cases a limited number have resulted in the successful management of clinical signs (Cornick et al. 1994; Moody et al.…”

Section: Introductionmentioning

confidence: 99%

Successful treatment of hyperkalaemic periodic paralysis in a horse during isoflurane anaesthesia

Pang

Panizzi

Paterson³

2011

Veterinary Anaesthesia and Analgesia

View full text Add to dashboard Cite

Hyperthermia during isoflurane anaesthesia in a horse with suspected hyperkalaemic periodic paralysis

Cited by 24 publications

References 8 publications

Malignant Hyperthermia Associated with Ryanodine Receptor 1 (C7360G) Mutation in Quarter Horses

Malignant Hyperthermia Associated with Ryanodine Receptor 1 (C7360G) Mutation in Quarter Horses

Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia

Successful treatment of hyperkalaemic periodic paralysis in a horse during isoflurane anaesthesia

Contact Info

Product

Resources

About